- Policy
- Coverage of 19 new drug items will be reinforced this year
- by Kim, Jung-Ju Aug 31, 2022 05:40am
- [Nineteen new drugs have been newly listed on the pharmaceutical reimbursement list or expanded reimbursement standards from January to this month this year. Among the drugs, 4 items were newly listed drugs, and 2 were already-listed drugs receiving reimbursement expansions. An estimated 1,320,371 patients will benefit from the new drug cove
- Policy
- Reevaluation of Amosartan plus & Twotops Plus
- by Lee, Tak-Sun Aug 30, 2022 05:55am
- Hanmi's Amosartan plus & Twotops plus cause the same formulation, whether or not listed. The Ministry of Health and Welfare announced the plan to revalue the addition in November 2020, and said that IMD will maintain its addition if the number of companies with the same product registered, individual single agents, complex agents, and admin
- Policy
- Lorviqua reimb at ₩52,819, Emgality at ₩295,250
- by Kim, Jung-Ju Aug 30, 2022 05:55am
- ◆Lorviqua Tab= Lorviqua is a treatment that received domestic marketing authorization as monotherapy to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC). The company applied for reimbursement after receiving approval from the Ministry of Food and Drug Safety on July 29
- Policy
- Zemimet’s price drops 9.7% in 5 years…discounted 5 times
- by Lee, Tak-Sun Aug 30, 2022 05:54am
- LG Chem’s incrementally modified new diabetes treatment, ‘Zemimet Tab,’ has once again been subject to Price-Volume Agreement negotiations this year and its price will be discounted as of the 1st of next month. This is the fifth price cut made through the PVA system for the drug since its reimbursement approval. Its price had fallen nearly
- Policy
- Kyowa Hakogirtin Postelligeo 20mg is expected to be approved
- by Lee, Hye-Kyung Aug 30, 2022 05:54am
- Posteligeo 20mg, a rare two-type non-Hodgkin lymphoma treatment of Kyowa Hakogirin, is expected to be approved. It has been four years since the U.S. Food and Drug Administration (FDA) approved the treatment of mycosis fungoids (MF) or S&233;zary syndrome (SS) in August 2018. According to the pharmaceutical industry on the 26th, the Ministry
- Policy
- "Raise the prescription rate for high-risk patients to 50%"
- by Lee, Jeong-Hwan Aug 29, 2022 06:03am
- Experts have pointed out that high-risk patients with COVID-19 should be first administered oral treatments such as Paxlovid or Lagevrio etc. before hospitalization. In other words, if the prescription rate of oral COVID-19 treatments remains in the current 20% range, experts believe that the prescriptions will not be sufficient to prev
- Policy
- NHI turns to deficit with a mere 2.6% coverage improvement
- by Lee, Jeong-Hwan Aug 26, 2022 05:35am
- With the new government preparing for complete reorganization and faceoff of the national health insurance coverage enhancement project ‘Moon Jae-In Care,' the ruling party criticized that Mooncare's implementation turned the current NHI balance into a deficit while raising the coverage rate by only a mere 2.6% points. Also, the party cr
- Policy
- Pts with osteopenia need screening tx
- by Kim, Jung-Ju Aug 26, 2022 05:35am
- The National Evidence-based Healthcare Collaborating Agency (Director Han Kwang-hyeop, NECA) analyzed the drug effect in osteopenia patients and developed a fracture risk prediction model and published the results of the study on the 25th. As aging rapidly progresses worldwide, the prevalence of osteopenia and osteoporosis is rapidly incre
- Policy
- MET mutant anticancer drug Tepmetko challenges
- by Lee, Tak-Sun Aug 25, 2022 05:52am
- Following the MET mutant anti-cancer drug Tabrecta, which landed in Korea last year, Tepmetko is also undergoing a review. MET mutations occur only in about 3-4% of non-small cell lung cancer patients, but the prognosis is poor, so there is a desperate need for treatments that are covered by benefits. According to an industry on the 24t
- Policy
- Entry of HER2-low breast cancer Tx imminent in Korea
- by Lee, Hye-Kyung Aug 25, 2022 05:52am
- Daiichi Sankyo Korea and AstraZeneca Korea’s human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) “Enhertu Inj (trastuzumab deruxtecan)” is expected to be approved in Korea soon. This imminent entry of the first treatment for HER2-low breast cancer in Korea attracting much attention. According to i
